Systemic cancer immunotherapy with Toll-like receptor 7 agonists: Timing is everything

Toll-like receptor (TLR) 7 agonists represent a promising strategy for the immunotherapy of cancer. We have recently investigated the influence of TLR tolerance on the efficacy of systemic tumor treatment with TLR7 ligands. We propose that considering the kinetics of receptor sensitivity highly impr...

Descripción completa

Detalles Bibliográficos
Autores principales: Hotz, Christian, Bourquin, Carole
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3376978/
https://www.ncbi.nlm.nih.gov/pubmed/22720251
http://dx.doi.org/10.4161/onci.1.2.18169
_version_ 1782235894938337280
author Hotz, Christian
Bourquin, Carole
author_facet Hotz, Christian
Bourquin, Carole
author_sort Hotz, Christian
collection PubMed
description Toll-like receptor (TLR) 7 agonists represent a promising strategy for the immunotherapy of cancer. We have recently investigated the influence of TLR tolerance on the efficacy of systemic tumor treatment with TLR7 ligands. We propose that considering the kinetics of receptor sensitivity highly improves the outcome of cancer immunotherapy.
format Online
Article
Text
id pubmed-3376978
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-33769782012-06-20 Systemic cancer immunotherapy with Toll-like receptor 7 agonists: Timing is everything Hotz, Christian Bourquin, Carole Oncoimmunology Author's View Toll-like receptor (TLR) 7 agonists represent a promising strategy for the immunotherapy of cancer. We have recently investigated the influence of TLR tolerance on the efficacy of systemic tumor treatment with TLR7 ligands. We propose that considering the kinetics of receptor sensitivity highly improves the outcome of cancer immunotherapy. Landes Bioscience 2012-03-01 /pmc/articles/PMC3376978/ /pubmed/22720251 http://dx.doi.org/10.4161/onci.1.2.18169 Text en Copyright © 2012 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Hotz, Christian
Bourquin, Carole
Systemic cancer immunotherapy with Toll-like receptor 7 agonists: Timing is everything
title Systemic cancer immunotherapy with Toll-like receptor 7 agonists: Timing is everything
title_full Systemic cancer immunotherapy with Toll-like receptor 7 agonists: Timing is everything
title_fullStr Systemic cancer immunotherapy with Toll-like receptor 7 agonists: Timing is everything
title_full_unstemmed Systemic cancer immunotherapy with Toll-like receptor 7 agonists: Timing is everything
title_short Systemic cancer immunotherapy with Toll-like receptor 7 agonists: Timing is everything
title_sort systemic cancer immunotherapy with toll-like receptor 7 agonists: timing is everything
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3376978/
https://www.ncbi.nlm.nih.gov/pubmed/22720251
http://dx.doi.org/10.4161/onci.1.2.18169
work_keys_str_mv AT hotzchristian systemiccancerimmunotherapywithtolllikereceptor7agoniststimingiseverything
AT bourquincarole systemiccancerimmunotherapywithtolllikereceptor7agoniststimingiseverything

Ejemplares similares